North America Hemophilia Management Market

NORTH AMERICA Hemophilia Management Market
The North America Hemophilia Management Market was worth $1.81 billion in 2015 and
estimated to be growing at a CAGR of 1.52%, to reach $1.96 billion by 2020. Hemophilia is a
genetic disorder which impairs body`s ability to control blood clotting.
Hemophilia is categorized into three levels depending on its severity as severe, moderate
and mild. About 80% of the hemophilia patients are considered to suffer from severe type.
CDC estimates that in United States one in every 5000 newborn children is affected by
Hemophilia A and one in every 30,000 is suffering from hemophilia B
North America hemophilia management market is driven by key factors such as growing
prevalence of the disease; increasing usage of recombinant product, technological
advancements. Rising investments in Research and developments for hemophilia products is
also a major factor fuelling the growth of the market. However lack of available medication,
stringent regulatory approvals and high cost of treatment are the key factors hindering the
market growth.
North American market for Hemophilia management is segmented on the basis of type of
hemophilia and drug. By type of hemophilia it is analysed as Hemophilia A and Hemophilia
B. On the basis drug the market is segmented into Octocogalfa, Nonacogalfa, Desmopressin
and other drugs. Hemophilia A is the largest segement and also estimated to be the fastest
growing segment during the forecast period due to large number of patients suffering from
hemophilia A
Based on geography North America hemophilia management market is analyzed under two
regions namely United States and Canada. North America is the largest market for
hemophilia management accounting for approximately XX%. With North America, United
States is the largest market for hemophilia management due to high government support
and the increasing number of patients suffering from hemophilia. Canada is estimated to be
the fastest growing region due to high growth potential due to increasing usage of available
medication.
Some of the major companies discussed in the report are Biogen, Baxter International Inc.,
Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring,
Octapharma and Swedish Orphan Biovitrum AB
TABLE OF CONTENT
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
+1 888-702-9626 | www.marketdataforecast.com | contact@marketdataforecast.com